Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...298299300301302303304305306307308...10661067»
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  Nutritional management of individuals with SARS-CoV-2 infection during rehabilitation. (Pubmed Central) -  Jul 2, 2022   
    COVID-19 patients are prone to malnutrition and sarcopenia due to inactivity, comorbidities, cytokine response, nutritional deficiencies, anosmia, loss of taste, anorexia and treatment with dexamethasone...COVID-19 patients have increased energy (27-30 kcal/day) and protein needs (1-1.5 g/kg body weight/day). Personalized nutritional education and counseling, food fortification with energy dense and/or protein rich whole foods or with powdered supplements and use of high protein, energy dense oral nutritional supplements are recommended.
  • ||||||||||  prednisone / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    Clinical, Journal:  Predictors of osteonecrosis in systemic lupus erythematosus: A prospective cohort study. (Pubmed Central) -  Jul 1, 2022   
    African American patients with systemic lupus erythematosus are at double the risk of experiencing ON compared to White patients. Oral prednisone at 20-39 mg for more than 1 month, or 40 mg daily for even 1 month, at any point in the disease course, remained the most important glucocorticoid predictor of ON.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Journal:  A Case of Bladder Plasmacytoma Diagnosed during Treatment of Multiple Myeloma (Pubmed Central) -  Jul 1, 2022   
    The patient was diagnosed with plasmacytoma. The patient was treated with radiation therapy for plasmacytoma of the bladder and surrounding lymph nodes, and then with daratumumab and dexamethasone for multiple myeloma for one year; however, the patient died because of worsening of multiple myeloma.
  • ||||||||||  budesonide/salbutamol (PT027) / AstraZeneca, Avillion
    Journal:  Comparison of the Microhardness of Surface Enamel Exposed to Anti-asthmatic Inhalants. (Pubmed Central) -  Jul 1, 2022   
    This research allowed us to know the values of the microhardness of the superficial enamel after being exposed to different anti-asthmatic inhalers that are indicated in daily clinical practice. Therefore, it is important to evaluate this microhardness since the use of different inhalers is very prevalent.
  • ||||||||||  Nasonex (mometasone furoate nasal spray) / Merck (MSD)
    Journal:  The add-on effect of an intranasal antihistamine with an intranasal corticosteroid in Japanese cedar pollinosis. (Pubmed Central) -  Jul 1, 2022   
    This article reviews the literature surrounding the CCR2 and CCR5 pathways, their proposed role in COVID-19, and the potential role of CVC to improve outcomes. The intranasal antihistamine provided better control of not only nasal symptoms, but also of ocular symptoms, and decreased the need for rescue medications when added to intranasal corticosteroid treatment in JCP patients.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal:  Mantle cell lymphoma negative for t(11,14) involving the kidneys: a case report. (Pubmed Central) -  Jul 1, 2022   
    We present a case of a rare presentation of Mantle cell lymphoma while describing the clinical presentation and diagnostic and treatment approaches. This case report can assist physicians in the clinical work-up and treatment of patients with similar diagnosis or presentation.
  • ||||||||||  Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
    Observational data, Journal:  Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England. (Pubmed Central) -  Jul 1, 2022   
    In total, 3536 patients initiated fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) SITT for the first time: 65% had a Medical Research Council (MRC) dyspnea score ≥3, 45% had forced expiratory volume in 1 second (FEV)% predicted <50%, and 64% had a moderate or severe exacerbation in the previous 12 months...First-time triple therapy was frequently initiated in patients with COPD inadequately controlled on maintenance therapy. General practitioners in England generally identify appropriate patients who require initiation of triple therapy.
  • ||||||||||  BMS-345541 / BMS
    Journal:  Repositioning of Anti-Inflammatory Drugs for the Treatment of Cervical Cancer Sub-Types. (Pubmed Central) -  Jul 1, 2022   
    We proposed 4 novels anti-inflammatory drugs (AS-601245, betamethasone, narciclasin, and methylprednisolone) for the treatment of HPV-16, 3 novel drugs for the treatment of HPV-18 (daphnetin, phenylbutazone, and tiaprofenoic acid), and 5 novel drugs (aldosterone, BMS-345541, etodolac, hydrocortisone, and prednisolone) for the treatment of both subtypes. We proposed anti-inflammatory drug candidates that have the potential to be therapeutic agents for the prevention and/or treatment of cervical cancer.
  • ||||||||||  dexamethasone injection / Generic mfg.
    Trial completion date, Trial primary completion date:  Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) (clinicaltrials.gov) -  Jul 1, 2022   
    P3,  N=520, Active, not recruiting, 
    We proposed anti-inflammatory drug candidates that have the potential to be therapeutic agents for the prevention and/or treatment of cervical cancer. Trial completion date: May 2022 --> Jun 2023 | Trial primary completion date: May 2022 --> Dec 2022
  • ||||||||||  dexamethasone / Generic mfg., epinephrine / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  LIBERATE - LIposomal Bupivacaine vERsus Adjuncts in Total shouldErs (clinicaltrials.gov) -  Jul 1, 2022   
    P4,  N=90, Completed, 
    Trial completion date: May 2022 --> Jun 2023 | Trial primary completion date: May 2022 --> Dec 2022 Recruiting --> Completed | Trial completion date: Jan 2024 --> Mar 2022 | Trial primary completion date: Jan 2024 --> Jan 2022
  • ||||||||||  prednisone / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    Treatment of Acute Optic Neuritis and MS Relapses: A Survey of Clinician Attitudes, Perspectives, and Clinical Reasoning (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) -  Jun 30, 2022 - Abstract #CMSC2022CMSC_624;    
    Most clinicians endorse an evidence gap regarding optimal AON treatment—particularly concerning since most use AON data to guide treatment of MS relapses in general. Our findings suggest that an AON study with broader treatment interventions and sensitive structural and functional outcomes may help address this need.
  • ||||||||||  fluocinonide / Generic mfg.
    Trial completion date:  Cutaneous Lupus Medication Experience Study (clinicaltrials.gov) -  Jun 30, 2022   
    P=N/A,  N=11, Active, not recruiting, 
    Our findings suggest that an AON study with broader treatment interventions and sensitive structural and functional outcomes may help address this need. Trial completion date: Jun 2022 --> Dec 2022
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Trial completion date, Trial primary completion date:  Steroid-reducing Effects of Crisaborole (clinicaltrials.gov) -  Jun 30, 2022   
    P4,  N=60, Recruiting, 
    Although both groups provide statistically significant pain relief, patients who received combined sacroiliac joint injection have significantly greater clinical improvement as regard to those who received only intraarticular injection. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Clinical, Journal:  Surgical Management of Ocular Cicatricial Pemphigoid in a Pediatric Patient. (Pubmed Central) -  Jun 29, 2022   
    Our findings demonstrated that Dex may play a role in the prevention of metastasis in this cell line. Tarsal fracture surgery may be considered part of the treatment in pediatric patients with stable ocular cicatricial pemphigoid presenting with severe entropion and trichiasis.
  • ||||||||||  Melflufen (melphalan flufenamide) / Oncopeptides
    Journal:  Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma. (Pubmed Central) -  Jun 29, 2022   
    Further clinical utilization in earlier lines of therapy is under review, pending the in-depth safety analysis by the FDA. The FDA approval of melflufen in combination with dexamethasone provides an additional therapy option for patients with heavily pretreated relapsed and refractory multiple myeloma.
  • ||||||||||  prednisone / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    Journal:  A case of IgG4-related disease exclusively affecting pia matter and cerebral parenchyma (Pubmed Central) -  Jun 29, 2022   
    Intravenous methylprednisolone therapy followed by oral prednisone induction markedly improved the cognitive functions and MRI findings detected at the initial diagnosis. Our case highlights the importance of including IgG4-RD as one of the differential diagnosis when encountering the patients suffering from isolated cranial lesions even in the absence of normal serum IgG4 level.
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Journal:  Eosinophilic granulomatosis with polyangiitis presenting with ischemic optic neuropathy (Pubmed Central) -  Jun 29, 2022   
    High dose intravenous methylprednisolone was started on presentation, but the patient showed no improvement in visual function. Although a rare complication, ischemic optic neuropathy associated with EGPA should be noted, as this is an emergent condition and requires prompt diagnosis and treatment.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Preclinical, Review, Journal:  Mifepristone's effects on depression- and anxiety-like behavior in rodents. (Pubmed Central) -  Jun 29, 2022   
    Future studies could aim to confirm the role of GRs and evaluate the contribution of PRs/ARs to the effects of mifepristone. Such studies will contribute to a better understanding of depression, anxiety, and other mood disorders and develop novel strategies, particularly for treatment-resistant conditions.